PMID- 29147972
OWN - NLM
STAT- MEDLINE
DCOM- 20191004
LR  - 20200225
IS  - 1615-6692 (Electronic)
IS  - 0340-9937 (Linking)
VI  - 44
IP  - 4
DP  - 2019 Jun
TI  - Plasma osteopontin levels in patients with dilated and hypertrophic 
      cardiomyopathy.
PG  - 347-353
LID - 10.1007/s00059-017-4645-3 [doi]
AB  - BACKGROUND: Osteopontin (OPN) is an extracellular matrix glycoprotein that plays 
      a role in a variety of cellular activities associated with inflammatory and 
      fibrotic responses. Increased OPN levels in myocardium and plasma have been 
      demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is 
      known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). 
      Therefore, the aim of our study was to compare plasma OPN levels in patients with 
      these two most common cardiomyopathies. PATIENTS AND METHODS: We examined plasma 
      OPN as well as creatinine, C‑reactive protein (CRP), brain-type natriuretic 
      peptide (BNP), and troponin I levels in 64 patients with DCM, 43 patients with 
      HCM, and 75 control subjects. Transthoracic echocardiography was also performed 
      on all cardiomyopathy patients. RESULTS: Plasma OPN levels were significantly 
      elevated in patients with DCM compared with HCM patients (95 +/- 43 vs. 57 +/- 
      21 ng/ml; p < 0.001) and control subjects (54 +/- 19 ng/ml; p < 0.001); however, 
      there was no difference between HCM patients and control subjects. New York Heart 
      Association (NYHA) class III or IV disease was more frequently present in DCM 
      patients than in HCM subjects (44 % vs. 2 %, p < 0.0001). In multivariate 
      analysis, BNP and CRP levels together with NYHA class were found to be 
      significant predictors of plasma OPN levels in DCM patients (p = 0.002, p = 
      0.029, and p < 0.001 for BNP, CRP, and NYHA, respectively). CONCLUSION: Plasma 
      OPN levels were associated with overall heart failure severity rather than with 
      specific cardiomyopathy subtype in patients suffering from DCM or HCM, 
      respectively.
FAU - Podzimkova, J
AU  - Podzimkova J
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, 
      U Nemocnice 2, 128 08, Prague, Czech Republic.
FAU - Palecek, T
AU  - Palecek T
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, 
      U Nemocnice 2, 128 08, Prague, Czech Republic. tpalec@lf1.cuni.cz.
FAU - Kuchynka, P
AU  - Kuchynka P
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, 
      U Nemocnice 2, 128 08, Prague, Czech Republic.
FAU - Marek, J
AU  - Marek J
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, 
      U Nemocnice 2, 128 08, Prague, Czech Republic.
FAU - Danek, B A
AU  - Danek BA
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, 
      U Nemocnice 2, 128 08, Prague, Czech Republic.
FAU - Jachymova, M
AU  - Jachymova M
AD  - Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of 
      Medicine, Charles University and General University Hospital in Prague, Prague, 
      Czech Republic.
FAU - Kalousova, M
AU  - Kalousova M
AD  - Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of 
      Medicine, Charles University and General University Hospital in Prague, Prague, 
      Czech Republic.
FAU - Zima, T
AU  - Zima T
AD  - Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of 
      Medicine, Charles University and General University Hospital in Prague, Prague, 
      Czech Republic.
FAU - Linhart, A
AU  - Linhart A
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, 
      U Nemocnice 2, 128 08, Prague, Czech Republic.
LA  - eng
PT  - Journal Article
TT  - Osteopontinspiegel im Plasma bei dilatativer und hypertrophischer 
      Kardiomyopathie.
DEP - 20171116
PL  - Germany
TA  - Herz
JT  - Herz
JID - 7801231
RN  - 106441-73-0 (Osteopontin)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - *Cardiomyopathy, Dilated/blood
MH  - *Cardiomyopathy, Hypertrophic/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardium
MH  - Natriuretic Peptide, Brain
MH  - *Osteopontin/blood
OTO - NOTNLM
OT  - Cardiomyopathies
OT  - Extracellular matrix glycoprotein
OT  - Heart failure
OT  - Myocardium
OT  - Ventricular remodeling
EDAT- 2017/11/18 06:00
MHDA- 2019/10/08 06:00
CRDT- 2017/11/18 06:00
PHST- 2017/08/20 00:00 [received]
PHST- 2017/10/22 00:00 [accepted]
PHST- 2017/10/16 00:00 [revised]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PHST- 2017/11/18 06:00 [entrez]
AID - 10.1007/s00059-017-4645-3 [pii]
AID - 10.1007/s00059-017-4645-3 [doi]
PST - ppublish
SO  - Herz. 2019 Jun;44(4):347-353. doi: 10.1007/s00059-017-4645-3. Epub 2017 Nov 16.